A novel small peptide as a targeting ligand for receptor tyrosine kinase Tie2

Biochemical and Biophysical Research Communications

Volumn 315, Issue 4, 2004, Pages 1004-1010

  Wu, Xianghua ^a,c   Zhao, Ruijiao ^a   Li, Zonghai ^a   Yao, Ming ^a   Wang, Huamao ^a   Han, Junsong ^a   Qu, Shumin ^a   Chen, Xianlian ^a   Qian, Lianfang ^a   Sun, Ye ^b   Xu, Yuhong ^a,b,d   Gu, Jianren ^a,d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d Shanghai New World Genom T ^*  (China)

Author keywords

Angiogenesis; Angiopoietin 2; Peptide ligand; Tie2; Tumor targeting

Indexed keywords

AMINO ACID; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; IODINE 125; LIGAND; PEPTIDE; PROTEIN TYROSINE KINASE; TYROSINE;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; INJECTION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TARGETING; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; TAIL; TISSUE; TUMOR XENOGRAFT; VEIN;

EID: 10744221092     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.01.157     Document Type: Article

References (31)

1. Riethmuller G., Schneider-Gadicke E., Johnson J.P. Monoclonal antibodies in cancer therapy. Curr. Opin. Immunol. 5:1993;732-739.
2. Mamot C., Drummond D.C., Greiser U., Hong K., Kirpotin D.B., Marks J.D., Park J.W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII- overexpressing tumor cells. Cancer Res. 63:2003;3154-3161.
3. Priebe W., Perez-Soler R. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacol. Ther. 60:1993;215-234.
4. De Jong M., Kwekkeboom D., Valkema R., Krenning E.P. Radiolabelled peptides for tumour therapy: current status and future directions plenary lecture at the EANM 2002. Eur. J. Nucl. Med. Mol. Imag. 30:2003;463-469.
5. Halin C., Gafner V., Villani M.E., Borsi L., Berndt A., Kosmehl H., Zardi L., Neri D. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res. 63:2003;3202-3210.
6. Langer M., Beck-Sickinger A.G. Peptides as carrier for tumor diagnosis and treatment. Curr. Med. Chem. Anti-Cancer Agents. 1:2001;71-93.
7. Barry M.A., Dower W.J., Johnston S.A. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat. Med. 2:1996;299-305.
8. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv Exhibits specific and high-level targeting of glioma xenografts. Clin. Cancer Res. 5:1999;1539-1549.
9. Thakur M.L. Radiolabelled peptides: now and the future. Nucl. Med. Commun. 16:1995;724-732.
10. De Palma M., Venneri M.A., Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum. Gene Ther. 14:2003;1193-1206.
11. Sawada N., Ishiwata T., Naito Z., Maeda S., Sugisaki Y., Asano G. Immunohistochemical localization of endothelial cell markers in solitary fibrous tumor. Pathol. Int. 52:2002;769-776.
12. Dales J.P., Garcia S., Bonnier P., Duffaud F., Meunier-Carpentier S., Andrac-Meyer L., Lavaut M.N., Allasia C., Charpin C. Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients. Int. J. Oncol. 22:2003;391-397.
13. Gunnarsson G.T., Desai U.R. Designing small, nonsugar activators of antithrombin using hydropathic interaction analyses. J. Med. Chem. 45:2002;1233-1243.
14. Abraham D.J., Kellogg G.E., Holt J.M., Ackers G.K. Hydropathic analysis of the non-covalent interactions between molecular subunits of structurally characterized hemoglobins. J. Mol. Biol. 272:1997;613-632.
15. Zelensky A.N., Gready J.E. Comparative analysis of structural properties of the C-type-lectin-like domain (CTLD). Proteins. 52:2003;466-477.
16. Procopio W.N., Pelavin P.I., Lee W.M., Yeilding N.M. Angiopoietin-1 and -2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activity. J. Biol. Chem. 274:1999;30196-30201.
17. Fiedler U., Krissl T., Koidl S., Weiss C., Koblizek T., Deutsch U., Martiny-Baron G., Marme D., Augustin H.G. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J. Biol. Chem. 278:2003;1721-1727.
18. Crim J.W., Garczynski S.F., Brown M.R. Approaches to radioiodination of insect neuropeptides. Peptides. 23:2002;2045-2051.
19. Folkman J., Hahnfeldt P., Hlatky L. Cancer: looking outside the genome. Nat. Rev. Mol. Cell. Biol. 1:2000;76-79.
20. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
21. Takahama M., Tsutsumi M., Tsujiuchi T. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin. Cancer Res. 5:1999;2506-2510.
22. Wurmbach J.H., Hammerer P., Sevinc S., Huland H., Ergun S. The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. Anticancer Res. 20:2000;5217-5220.
23. Lin P., Buxton J.A., Acheson A., Radziejewski C., Maisonpierre P.C., Yancopoulos G.D., Channon K.M., Hale L.P., Dewhirst M.W., George S.E., Peters K.G. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. USA. 95:1998;8829-8834.
24. Hruby V.J. Designing peptide receptor agonists and antagonists. Nat. Rev. Drug Discov. 1:2002;847-858.
25. Webb P., Anderson C.M., Valentine C., Nguyen P., Marimuthu A., West B.L., Baxter J.D., Kushner P.J. The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). Mol. Endocrinol. 14:2000;1976-1985.
26. Willam C., Koehne P., Jurgensen J.S., Grafe M., Wagner K.D., Bachmann S., Frei U., Eckardt K.U. Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ. Res. 87:2000;370-377.
27. Sun B.F., Kobayashi H., Le N., Yoo T.M., Drumm D., Paik C.H., McAfee J.G., Carrasquillo J.A. Effects of insulinlike growth factor binding proteins on insulin like growth factor-I biodistribution in tumor-bearing nude mice. J. Nucl. Med. 41:2000;318-326.
28. Servais H., Tulkens P.M. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob. Agents Chemother. 45:2001;2643-2647.
29. Venkatraman J., Nagana Gowda G.A., Balaram P. Design and construction of an open multistranded beta-sheet polypeptide stabilized by a disulfide bridge. J. Am. Chem. Soc. 124:2002;4987-4994.
30. Lee H., Jeong J.H., Park T.G. PEG grafted polylysine with fusogenic peptide for gene delivery: high transfection efficiency with low cytotoxicity. J. Control Release. 79:2002;283-291.
31. Casanovas J., Aleman C. A quantum-mechanical study of the chain-length dependent stability of the extended and 3(10)-helix conformations in dehydroalanine oligopeptides. J. Comput. Aided Mol. Des. 8:1994;441-448.